From latest qtr - probably related to thisOrthoATI™OrthoATI is a...

From latest qtr - probably related to this
OrthoATI™
OrthoATI is a world-leading cell therapy in development for the treatment
of chronic degenerative tendon injuries (tendinopathy/tendonitis).
OrthoATI can be used in both surgical and non-surgical applications and is
at the forefront of a large and increasing market opportunity, estimated
to be worth >US$7.7bn3 and growing.
During the quarter Orthocell announced results from its clinical study comparing OrthoATI to surgery for the
treatment of severe, chronic, treatment-resistant lateral epicondylitis (‘LE Study’). The data confirmed that
the study met its primary endpoint, demonstrating that OrthoATI is as effective as surgery in the treatment
of lateral epicondylitis. OrthoATI patients experienced almost complete resolution of pain by 1-month posttreatment compared to 6 months after treatment in the surgery group. Notably, participants in the OrthoATI
group demonstrated a statistically significant improvement of return of function in half the time than the
surgery group.
3 Addressable market estimate was developed by the Company using reports from US healthcare databases and referenced papers of studies
conducted both within and outside the US.
With this successful study in lateral epicondylitis completed, Orthocell is now well positioned to engage
partners to explore the next stage of development of the product for US FDA registration. The Company will
look to appoint a US based corporate adviserto assist the Company in securing a strategic partnerto progress
OrthoATI without the need for significant investment in the near term.